Member Info for BuenaVista

VS wrote "My understanding from CC is that a partnership decision is shelved until patents are granted."

I missed the webinar and haven't seen/heard the recording yet but this makes sense. Partnering won't be put on hold by Avacta but rather by any potential partners, who will need to be assured that AVA6103 has patent protection - i.e. a granted patent. AVA6000 has this protection (for another 10 years) so I assume she must have been referring to 'The Beast'.

@reapz234's "Funding needs to come soon, and only way this has happened in the past is via a retail raise or a Heights loan."

That was then, this is now. Quite a different situation.

Now ask him what AVA7103 is, and to get his Gens sorted out.

From Google:

"In the United States, there are approximately 10-15% of all breast cancer cases that are triple-negative breast cancer (TNBC). This translates to about 20,000 to 30,000 new TNBC cases diagnosed annually. For instance, in 2023, it was estimated that 298,000 new cases of breast cancer would be diagnosed, and TNBC would account for 10-15% of those cases. Additionally, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program indicates that TNBC affects approximately 13 in every 100,000 females in the U.S."

...and...

"Globally, an estimated 170,000 to 200,000 cases of triple-negative breast cancer (TNBC) are diagnosed each year. TNBC represents about 10-20% of all breast cancer diagnoses."

The webinar is clearly timed to catch the East coast's 1pm and the West coast's 10am. As far as I can ascertain the webinar has only been announced as an RNS, nothing specific for the US. Given the short notice and the need to get US IIs on board I'd not be at all surprised if the date and time had been arranged some time ago and given to important IIs well in advance. And then someone at Avacta realised it hadn't been officially announced.

Here's the page from October. There is a January version but it doesn't render properly formatted.

https://web.archive.org/web/20241003101638/https://avacta.com/investors/key-information/

Thanks. I had seen kcat/Km elsewhere and been wondering what it meant.

But you don't "read and listen to what AVCT say" do you. You don't follow the presentations or read the slide decks. You have to be pointed by us to the latest information. You have no insight into the data; you merely trade based on TA.

'Callous' is a good term for a trader so driven by the love of money.

What did YOU think was disapponting about the data?

Now there's a question you can write a chapter on. If you can answer the question.

"Clearly BG (with a specialised fund) saw the data as disappointing"

BG is not a specialised biopharma fund. The true reason why they sold (relatively or absolutely 'disappointing') is not known.

The management do an explainer after every release of data. Why should Thursday's event be any different?

Critcism taken Thompi, but who the hell keeps calling Nasdaq, Nazdaq when talking about Nasdaq all the time?

Ey up! The 12 year old is staying up past his bedtime.

Quite Timster. We'd probably learn more from asking the pub bore windbag.

Thank you for the suggestion D-G. A surprisingly long trek from Sliema but I'm there for a fortnight. Intending to go to the National War Museum at Fort St Elmo in Valletta to see a Spitfire fuselage if I can (it may be in storage) as it is from the plane flown by my mother's first fiance (later killed in a explosion whilst testing a new plane from the Castle Bromwich works) that was shot down over a bay on Gozo.

Short notice or took time to organise or forgot to put out the notification message. You never know with Avacta.🐵

@D-Geeman's "Inhalation allows the administration of high drug doses directly to lung tumors without prior distribution in the organism."

So the premise is that chemo drugs are preferentially absorbed by tumour cells in those cancers that are low in FAP ? Why is that so and not akin to inhaling bleach, which is indiscriminate?

Maybe ask CC whether they have tested a lung model by inhalation. Absorption through the lungs may or may not be difficult. It could depend on the permeability of the mucus layer that protects the lungs from foreign elements.

@Bella, if there is a move to Nasdaq-style quarterly updates then they'll have to be a LOT more detailed to fall in line with Nasdaq quarterly reporting.

And why do you call the market Nazdaq? Is this your Nazi leaning?

These will never get answered but I don't care. I'll be landing in Malta by then...

Q1. Why does CC not reply to private investors' emails?

Q2. Is CC aware of the glaring mistakes and inconsistencies that make the Avacta website and thus Avacta look very unprofessional? AVA7103 for instance?

Q3. Does CC believe Avacta has an effective communications strategy suitable for the AIM market?

Q4. From the Conclusions on the CT151 poster presented at AACR 2025: "... despite dosing up to 385 mg/m2 every 3 weeks (~4x conventional dose doxorubicin) ... Despite dosing up to 4x the dose of conventional doxorubicin ... conventional dose doxorubicin (75 mg/m2 Q3W)." 385 mg/m2 of AVA6000 contains 385 x 54/80 of doxorubicin, which is 260 mg/m2 of doxorubicin which is 3.47x the stated conventional dose doxorubicin of 75 mg/m2. Does CC regard it as acceptable for Avacta, credibility- and integrity-wise, to overstate the comparison to conventional dose doxorubicin by over 13%?

Https://www.youtube.com/watch?v=-IGrQtnfFoE&t=1380s 😁

You want to get your drug approved? How many meme coins did you say you'd bought?